Rchr
J-GLOBAL ID：202301009382825484
Update date: May. 09, 2024
Kawahara Naoki
カワハラ ナオキ | Kawahara Naoki
Affiliation and department：
Job title：
Assistant Professor
Research field (1)：
Obstetrics and gynecology
Research keywords (5)：
Cancer Metabolism
, Endometrioid associated ovarian cancer
, Ovarian endometrioma
, Ovarian cancer
, Gynecological cancer
Research theme for competitive and other funds (5)：
- 2023 - 2026 Study of the effects of oral dydrogesterone administration on fetal growth restriction
- 2023 - 2026 A study of the effect of hydroxychloroquine on repeated fetal loss and development of preeclampsia
- 2021 - 2024 The investigation in synthetic lethal effect of CCNE1 for ARID1A mutation in ovarian clear cell carcinoma
- 2020 - 2023 HNF1β-USP28-CLASPIN-Chk1阻害に対する合成致死候補の検索
- 2019 - 2022 Search for synthetic lethal candidates for PIK3CA mutations
Papers (39)：
-
Naoki Kawahara, Shoichiro Yamanaka, Kyohei Nishikawa, Motoki Matsuoka, Tomoka Maehana, Ryuji Kawaguchi, Naoki Ozu, Tomomi Fujii, Aya Sugimoto, Akihiko Yoshizawa, et al. Endogenous Microbacteria Can Contribute to Ovarian Carcinogenesis by Reducing Iron Concentration in Cysts: A Pilot Study. Microorganisms. 2024. 12. 3
-
Naoki Kawahara, Ryuji Kawaguchi, Konosuke Yamamoto, Kyohei Nishikawa, Motoki Matsuoka, Tomoka Maehana, Yosuke Fukui, Shoichiro Yamanaka, Sumire Sugimoto, Kana Iwai, et al. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial. Trials. 2024. 25. 1. 68-68
-
Naoki Kawahara, Shoichiro Yamanaka, Sumire Sugimoto, Junya Kamibayashi, Kyohei Nishikawa, Ryuji Kawaguchi, Fuminori Kimura. The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients. Cancers. 2023. 15. 20
-
Ryuji Kawaguchi, Tomoka Maehana, Shoichiro Yamanaka, Ryuta Miyake, Naoki Kawahara, Kana Iwai, Yuki Yamada, Fuminori Kimura. Preoperative serum tissue factor pathway inhibitor-2 level as a prognostic marker for endometrial cancer. Oncology Letters. 2023. 26. 5
-
Ryuji Kawaguchi, Tomoka Maehana, Sumire Sugimoto, Naoki Kawahara, Kana Iwai, Yuki Yamada, Fuminori Kimura. Immunohistochemical Analysis of the Tissue Factor Pathway Inhibitor-2 in Endometrial Clear Cell Carcinoma: A Single-center Retrospective Study. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2023
ｍore...
MISC (84)：
-
松岡 基樹, 山田 有紀, 竹田 佳奈, 美並 優希, 山本 皇之祐, 上林 潤也, 西川 恭平, 福井 陽介, 杉本 澄美玲, 河原 直紀, et al. 進行子宮体癌に対するレンバチニブ/ペムブロリズマブ療法中に心筋炎を発症した1例. 産婦人科の進歩. 2023. 75. 4. 561-561
-
河原 直紀, 山本 皇之祐, 福井 陽介, 山中 彰一郎, 山田 有紀, 岩井 加奈, 川口 龍二, 木村 文則. 卵巣癌における手術前後のデータを用いた予後予測スコアの確立と有効性. 産婦人科の進歩. 2023. 75. 2. 178-178
-
河原 直紀, 山本 皇之祐, 福井 陽介, 山中 彰一郎, 山田 有紀, 岩井 加奈, 川口 龍二, 木村 文則. 卵巣癌における手術前後のデータを用いた予後予測スコアの確立と有効性. 産婦人科の進歩. 2023. 75. 2. 178-178
-
梅原 健耶, 山田 有紀, 岩井 加奈, 山本 皇之祐, 上林 潤也, 脇 啓太, 福井 陽介, 山尾 佳穂, 杉本 澄美玲, 河原 直紀, et al. OHVIRA症候群に対するVaginoscopyを用いた腟中隔切除術. 日本生殖医学会雑誌. 2023. 68. 1-2. 150-150
-
綾野 沙羅, 山田 有紀, 藤井 健太, 山本 皇之祐, 上林 潤也, 松岡 基樹, 福井 陽介, 河原 直紀, 岩井 加奈, 川口 龍二, et al. 子宮体癌に対するLenvatinib/Pembrolizumab併用療法中に急性胆嚢炎を生じた一例. 日本産科婦人科学会雑誌. 2023. 75. 臨増. S-350
ｍore...
Books (1)：
-
子宮内膜症・子宮腺筋症 : 診断アトラス&新たな治療戦略
中山書店 2021 ISBN:9784521749105
Lectures and oral presentations (1)：
-
CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma
(2023)
Education (3)：
- 2021 - 2022 Wayne State University
- 2017 - 2021 Nara Medical University Graduate School of Medical Science Course
- 2003 - 2009 Nara Medical University Medical Faculty Medical Department
Work history (7)：
Awards (2)：
- 2024/01 - Japan Society of Endometriosis Presentation Award (Clinical)
- 2023/01 - Konica Minolta Science and Technology Foundation Imaging Science Incentive Award Development to Differentiate Malignant Endometriotic Cysts by Wide-Band Ultrasound Measurements
Association Membership(s) (4)：
日本婦人科腫瘍学会
, 日本周産期・新生児医学会
, 日本産科婦人科内視鏡学会
, 日本産科婦人科学会
